SCS Capital Management LLC Takes $565,000 Position in Annexon, Inc. $ANNX

SCS Capital Management LLC acquired a new position in shares of Annexon, Inc. (NASDAQ:ANNX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 99,000 shares of the company’s stock, valued at approximately $565,000. SCS Capital Management LLC owned about 0.06% of Annexon at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ANNX. Redmile Group LLC lifted its stake in Annexon by 44.8% in the 1st quarter. Redmile Group LLC now owns 14,549,768 shares of the company’s stock valued at $80,606,000 after purchasing an additional 4,499,124 shares during the last quarter. BVF Inc. IL increased its position in Annexon by 30.4% during the fourth quarter. BVF Inc. IL now owns 9,128,080 shares of the company’s stock worth $45,823,000 after buying an additional 2,128,080 shares during the last quarter. Vanguard Group Inc. raised its stake in Annexon by 8.7% in the third quarter. Vanguard Group Inc. now owns 5,835,112 shares of the company’s stock valued at $17,797,000 after buying an additional 469,073 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in Annexon by 266.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,500,000 shares of the company’s stock valued at $27,610,000 after buying an additional 4,000,000 shares during the period. Finally, State Street Corp lifted its position in shares of Annexon by 126.9% in the fourth quarter. State Street Corp now owns 4,652,185 shares of the company’s stock valued at $23,354,000 after buying an additional 2,601,877 shares during the last quarter.

Annexon Price Performance

Shares of NASDAQ:ANNX opened at $5.29 on Monday. Annexon, Inc. has a 12-month low of $2.03 and a 12-month high of $7.18. The business has a 50 day moving average of $5.35 and a 200-day moving average of $5.50. The stock has a market cap of $1.00 billion, a PE ratio of -4.56 and a beta of 1.18.

Annexon (NASDAQ:ANNX) last announced its earnings results on Wednesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). Equities research analysts expect that Annexon, Inc. will post -1 earnings per share for the current year.

Key Headlines Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $14 price target, substantially above the stock’s recent trading level near $5.29. The firm continues to project a path to profitability, with estimated positive EPS of $0.03 in 2029 and $0.45 in 2030. HC Wainwright earnings estimates and rating
• Neutral Sentiment: Citizens JMP upgraded Annexon to Market Perform, while WallStreetZen separately lowered its rating. The conflicting actions point to more cautious or mixed views among analysts rather than a clear change in the company’s fundamental outlook. Citizens JMP rating update WallStreetZen rating update
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026-2030, including Q3 2026 EPS to a $0.27 loss from a $0.22 loss, FY2026 to a $0.99 loss from $0.90, and FY2029 earnings to $0.03 from $0.13. The firm also cut its FY2030 estimate to $0.45 from $0.56. These revisions suggest higher expected losses or slower financial improvement. Annexon recently reported a quarterly loss of $0.28 per share, worse than the $0.24 consensus estimate. HC Wainwright revised estimates

Insider Buying and Selling

In other news, Director Muneer A. Satter acquired 613,497 shares of the stock in a transaction on Thursday, May 28th. The shares were purchased at an average price of $5.41 per share, for a total transaction of $3,319,018.77. Following the transaction, the director directly owned 10,342,134 shares of the company’s stock, valued at approximately $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.31% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ANNX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a report on Friday, July 17th. Citizens Jmp raised Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday. Wall Street Zen cut shares of Annexon from a “sell” rating to a “strong sell” rating in a research report on Saturday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Monday, July 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Annexon in a report on Monday, July 20th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Annexon has an average rating of “Hold” and an average price target of $15.33.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.